Table 2. Correlation between androgen receptor expression and clinicopathological parameters in triple negative breast cancer patients.
| AR- (%) | AR+ (%) | OR (CI) | p value | ||
|---|---|---|---|---|---|
| Menopausal status | 0.423 (0.247-0.709) | <0.001 | |||
| Pre- | 174 (86.6) | 27 (13.4) | |||
| Post- | 174 (73.1) | 64 (26.9) | |||
| T stage | 0.846 (0.667-1.070) | 0.153 | |||
| T1 | 438 (75.0) | 146 (25.0) | |||
| T2-4 | 774 (71.7) | 305 (28.3) | |||
| Pathology | 0.934 (0.641-1.380) | 0.716 | |||
| Ductal | 973 (72.9) | 362 (27.1) | |||
| Non Ductal | 113 (71.5) | 45 (28.5) | |||
| Histological grade | 2.317 (1.806-2.969) | <0.001 | |||
| Grade 1-2 | 223 (59.2) | 154 (40.8) | |||
| Grade 3 | 1047 (77.0) | 312 (23.0) | |||
| LVI | 1.082 (0.841-1.394) | 0.530 | |||
| No | 735 (71.1) | 299 (28.9) | |||
| Yes | 335 (72.7) | 126 (27.3) | |||
| Lymph-node metastasis | 0.723 (0.578-0.904) | <0.01 | |||
| No | 558 (77.4) | 163 (22.6) | |||
| Yes | 790 (71.2) | 319 (28.8) | |||
| Surgical treatment | 1.567 (0.919-2.748) | 0.085 | |||
| Mastectomy | 249 (73.9) | 88 (26.1) | |||
| Lumpectomy | 102 (81.6) | 23 (18.4) | |||
| Chemotherapy | 1.170 (0.619-2.137) | 0.584 | |||
| No | 45 (72.6) | 17 (27.4) | |||
| Yes | 771 (75.7) | 248 (24.3) |
AR: Androgen receptor; CI: Confidence interval LVI: Lymphovascular invasion; OR: Odds ratio;